Sorafenat 200 Use In Pregnancy & Lactation

Pregnancy: There are no data on the use of sorafenib in pregnant women. Studies in animals have shown reproductive toxicity including malformations (see Pharmacology: Toxicology: Preclinical safety data under Actions). In rats, sorafenib and its metabolites were demonstrated to cross the placenta and sorafenib is anticipated to cause harmful effects on the foetus. Sorafenib should not be used during pregnancy unless clearly necessary, after careful consideration of the needs of the mother and the risk to the foetus. Women of childbearing potential must use effective contraception during treatment.
Lactation: It is not known whether sorafenib is excreted in human milk. In animals, sorafenib and/or its metabolites were excreted in milk. Because sorafenib could harm infant growth and development (see Pharmacology: Toxicology: Preclinical safety data under Actions), women must not breast-feed during sorafenib treatment.
Fertility: Results from animal studies further indicate that sorafenib can impair male and female fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Women of childbearing potential/Contraception: In animals, sorafenib has been shown to be teratogenic and embryotoxic. Adequate contraception should be used during therapy and for at least 2 weeks after completion of therapy (see Precautions and Pharmacology: Toxicology: Preclinical safety data under Actions).